A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 4, 2011, Pages 387-398

  Pan, Xian ^a   Wang, Ping ^a   Hu, Nan ^a   Liu, Li ^a   Liu, Xiaodong ^a   Xie, Lin ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cytochrome P4501A2; Drug drug interaction; In vitro in vivo prediction; Mechanism based inhibition; Physiologically based pharmacokinetic model

Indexed keywords

ANTIINFECTIVE AGENT; ANTOFLOXACIN; CYTOCHROME P450 1A2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MORNING DOSAGE; NONHUMAN; PHYSIOLOGICAL PROCESS; PREDICTION; QUANTITATIVE ANALYSIS; RAT; SINGLE DRUG DOSE;

EID: 80052556033     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-126     Document Type: Article

References (46)

1. Wijnands, W. J., van Herwaarden, C. L. and Vree, T. B.: Enoxacin raises plasma theophylline concentrations. Lancet, 2: 108-109 (1984).
2. Edwards, D. J., Bowles, S. K., Svensson, C. K. and Rybak, M. J.: Inhibition of drug metabolism by quinolone antibiotics. Clin. Pharmacokinet., 15: 194-204 (1988).
3. Fuhr, U., Anders, E. M., Mahr, G., Sorgel, F. and Staib, A. H.: Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob. Agents Chemother., 36: 942-948 (1992).
4. Herrlin, K., Segerdahl, M., Gustafsson, L. L. and Kalso, E.: Methadone, ciprofloxacin, and adverse drug reactions. Lancet, 356: 2069-2070 (2000).
5. Kunii, T., Fukasawa, T., Yasui-Furukori, N., Aoshima, T., Suzuki, A., Tateishi, T., Inoue, Y. and Otani, K.: Interaction study between enoxacin and fluvoxamine. Ther. Drug Monit., 27: 349-353 (2005).
6. Matuschka, P. R. and Vissing, R. S.: Clinafloxacin-theophylline drug interaction. Ann. Pharmacother., 29: 378-380 (1995).
7. Xiao, Y., Lu, Y., Kang, Z., Hou, F., Wang, S., Li, T., Liu, Y. and Xia, Y.: Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int. J. Clin. Pharmacol. Ther., 46: 172-179 (2008).
8. Xiao, Y., Lu, Y., Kang, Z., Zhang, M., Liu, Y., Zhang, M. and Li, T.: Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm. Drug Dispos., 29: 167-172 (2008).
9. Wang, J., Xiao, Y., Lu, Y., Kang, Z., Zhang, M., Liu, Y., Liang, J., Zhang, M. and Li, T.: Pharmacokinetics of antofloxacin hydrochloride, a novel fluoroquinolone, after single-dose intravenous administration in healthy Chinese male volunteers. Xenobiotica, 40: 344-349 (2010).
10. Wang, J., Xiao, Y., Huang, W., Xu, N., Bai, C., Xiu, Q., Mei, C. and Zheng, Q.: A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections. Chemotherapy, 56: 378-385 (2010).
11. Ogilvie, R. I.: Clinical pharmacokinetics of theophylline. Clin. Pharmacokinet., 3: 267-293 (1978).
12. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal. Biochem., 72: 248-254 (1976).
13. Rogge, M. C., Solomon, W. R., Sedman, A. J., Welling, P. G., Toothaker, R. D. and Wagner, J. G.: The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. Clin. Pharmacol. Ther., 44: 579-587 (1988).
14. Grygiel, J. J., Miners, J. O., Drew, R. and Birkett, D. J.: Differential effects of cimetidine on theophylline metabolic pathways. Eur. J. Clin. Pharmacol., 26: 335-340 (1984).
15. Gu, L., Gonzalez, F. J., Kalow, W. and Tang, B. K.: Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA expressed human CYP1A2 and CYP2E1. Pharmacogenetics, 2: 73-77 (1992).
16. Niki, Y., Ito, K. and Okazaki, O.: Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrob. Agents Chemother., 42: 1751-1755 (1998).
17. Zhu, Q., Liao, J., Xie, L., Wang, G. J. and Liu, X. D.: Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica, 39: 293-301 (2009).
18. Liu, X. Q., Zhao, Y., Qian, Z. Y. and Wang, G. J.: Metabolism and metabolic inhibition of clinipine in human liver microsomes. Acta Pharmacol. Sin., 24: 263-268 (2003).
19. Sarkar, M., Polk, R. E., Guzelian, P. S., Hunt, C. and Karnes, H. T.: In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob. Agents Chemother., 34: 594-599 (1990).
20. Kim, E. J., Suh, O. K. and Lee, M. G.: Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. Life Sci., 72: 1231-1245 (2003).
21. Leblond, F., Guevin, C., Demers, C., Pellerin, I., Gascon-Barre, M. and Pichette, V.: Downregulation of hepatic cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol., 12: 326-332 (2001).
22. Wang, X., Liu, Y. P., Shen, W. J., Zhang, X. Z. and Di, X.: Pharmacokinetics and relative bioavailability of compound amino-phylline bromhexine and chlorphenamine tablets in healthy volunteers. Chin. J. Pharmaceutics, 8: 33-38 (2010).
23. Zhang, D., Zhu, M. S. and Humphreys, W. G.: Analysis of in vitro cytochrome P450 inhibition in drug discovery and development: Drug Metabolism in Drug Design and Development. Hoboken, New Jersey, John Wiley & Sons, Inc. Press, 2008, pp. 523-524.
24. Kanamitsu, S. I., Ito, K., Green, C. E., Tyson, C. A., Shimada, N. and Sugiyama, Y.: Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm. Res., 17: 419-426 (2003).
25. Tjia, J. F., Colbert, J. and Back, D. J.: Theophylline metabolism in human liver microsomes: inhibition studies. J. Pharmacol. Exp. Ther., 276: 912-917 (1996).
26. Nix, D. E., DeVito, J. M., Whitbread, M. A. and Schentag, J. J.: Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J. Antimicrob. Chemother., 19: 263-269 (1987).
27. Nix, D. E. and Schentag, J. J.: The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J. Clin. Pharmacol., 28: 169-178 (1988).
28. Robson, R. A., Begg, E. J., Atkinson, H. C., Saunders, D. A. and Frampton, C. M.: Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. Br. J. Clin. Pharmacol., 29: 491-493 (1990).
29. Teunissen, M. W., Brorens, I. O., Geerlings, J. M. and Breimer, D. D.: Dose-dependent elimination of theophylline in rats. Xenobiotica, 15: 165-171 (1985).
30. Raghavan, S., Shen, C. J., Desai, R. A., Sniadecki, N. J., Nelson, C. M. and Chen, C. S.: Decoupling diffusional from dimensional control of signaling in 3D culture reveals a role for myosin in tubulogenesis. J. Cell Sci., 123: 2877-2883 (2010).
31. Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P. and Selkoe, D. J.: Enhanced proteolysis of Ç-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron, 40: 1087-1093 (2003).
32. Ogawa, N., Satsu, H., Watanabe, H., Fukaya, M., Tsukamoto, Y., Miyamoto, Y. and Shimizu, M.: Acetic acid suppresses the increase in disaccharidase activity that occurs during culture of Caco-2 cells. J. Nutr., 130(3): 507-513 (2000).
33. McLellan, R. A., Drobitch, R. K., Monshouwer, M. and Renton, K. W.: Fluoroquinolone antibiotics inhibit cytochrome P450- mediated microsomal drug metabolism in rat and human. Drug Metab. Dispos., 24(10): 1134-1138 (1996).
34. Bilbao, M. G., di Yorio, M. P. and Faletti, A. G.: Differential effects of leptin on ovarian metalloproteinases and their tissue inhibitors between in vivo and in vitro studies. J. Endocrinol., 209(1): 65-74 (2011).
35. Quinney, S. K., Zhang, X., Lucksiri, A., Gorski, J. C., Li, L. and Hall, S. D.: Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab. Dispos., 38: 241-248 (2010).
36. Bernareggi, A. and Rowland, M.: Physiologic modeling of cyclosporin kinetics in rat and man. J. Pharmacokinet. Biopharm., 19: 21-50 (1991).
37. Davies, B. and Morris, T.: Physiological parameters in laboratory animals and humans. Pharm. Res., 10: 1093-1095 (1993).
38. Björkman, S.: Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modeling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol., 59: 691-704 (2005).
39. Pang, X. Y., Xie, L., Xu, X., Liu, L. and Liu, X. D.: Pharmacokinetics of antofloxacin in rats co-administered with non-steroidal anti-inflammatory drugs. Chin. J. New Drugs, 16: 600-603 (2007).
40. Lu, P., Schrag, M. L., Slaughter, D. E., Raab, C. E., Shou, M. and Rodrigues, A. D.: Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab. Dispos., 31: 1352-1360 (2003).
41. Ito, K. and Houston, J.: Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res., 21: 785-792 (2004).
42. Kanamitsu, S. I., Ito, K., Okuda, H., Ogura, K., Watabe, T., Muro, K. and Sugiyama, Y.: Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl) uracil. Drug Metab. Dispos., 28: 467-474 (2000).
43. Paalzow, L. K.: Pharmacokinetics of theophylline in relation to increased pain sensitivity in the rat. J. Pharmacokinet. Biopharm., 3: 25-38 (1975).
44. Staib, A. H., Loew, D., Harder, S. and Pfab, R.: Measurement of theophylline absorption from different regions of the gastrointestinal tract using a remote controlled drug delivery device. Eur. J. Clin. Pharmacol., 30: 691-697 (1986).
45. Iwatsubo, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., Yokoi, T., Kamataki, T. and Sugiyama, Y.: Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J. Pharmacol. Exp. Ther., 282: 909-919 (1997).
46. Haruta, S., Kawai, K., Nishii, R., Jinnouchi, S., Ogawara, K., Higaki, K., Tamura, S., Arimori, K. and Kimura, T.: Prediction of plasma concentration-time curve of orally administered theophylline based on a scintigraphic monitoring of gastrointestinal transit in human volunteers. Int. J. Pharm., 233: 179-190 (2002).